| Year |
Citation |
Score |
| 2024 |
Mai N, Dos Anjos CH, Razavi P, Safonov A, Patil S, Chen Y, Drago JZ, Modi S, Bromberg JF, Dang CT, Liu D, Norton L, Robson M, Chandarlapaty S, Jhaveri K. Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer. Npj Breast Cancer. 10: 92. PMID 39424631 DOI: 10.1038/s41523-024-00699-3 |
0.373 |
|
| 2024 |
Kudo R, Safonov A, Jones C, Moiso E, Dry JR, Shao H, Nag S, da Silva EM, Yildirim SY, Li Q, O'Connell E, Patel P, Will M, Fushimi A, Benitez M, ... ... Razavi P, et al. Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion. Cancer Cell. PMID 39393354 DOI: 10.1016/j.ccell.2024.09.009 |
0.372 |
|
| 2024 |
Safonov A, Marra A, Bandlamudi C, O'Leary B, Wubbenhorst B, Ferraro E, Moiso E, Lee M, An J, Donoghue MTA, Will M, Pareja F, Nizialek E, Lukashchuk N, Sofianopoulou E, ... ... Razavi P, et al. Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer. Biorxiv : the Preprint Server For Biology. PMID 39253462 DOI: 10.1101/2024.02.05.578934 |
0.408 |
|
| 2024 |
Jee J, Brannon AR, Singh R, Derkach A, Fong C, Lee A, Gray L, Pichotta K, Luthra A, Diosdado M, Haque M, Guo J, Hernandez J, Garg K, Wilhelm C, ... ... Razavi P, et al. DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism. Nature Medicine. PMID 39147831 DOI: 10.1038/s41591-024-03195-0 |
0.358 |
|
| 2024 |
Jhaveri K, Mai N, Dos Anjos CH, Razavi P, Safonov A, Patil S, Chen Y, Drago J, Modi S, Bromberg J, Dang C, Liu D, Norton L, Robson M, Chandarlapaty S. Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Failure in ER+ Metastatic Breast Cancer. Research Square. PMID 38746324 DOI: 10.21203/rs.3.rs-4237867/v1 |
0.373 |
|
| 2024 |
Gupta A, Gazzo A, Selenica P, Safonov A, Pareja F, da Silva EM, Brown DN, Zhu Y, Patel J, Blanco-Heredia J, Stefanovska B, Carpenter MA, Pei X, Frosina D, Jungbluth AA, ... ... Razavi P, et al. APOBEC3 mutagenesis drives therapy resistance in breast cancer. Biorxiv : the Preprint Server For Biology. PMID 38746158 DOI: 10.1101/2024.04.29.591453 |
0.442 |
|
| 2024 |
Blawski R, Vokshi BH, Guo X, Kittane S, Sallaku M, Chen W, Gjyzari M, Cheung T, Zhang Y, Simpkins C, Zhou W, Kulick A, Zhao P, Wei M, Shivashankar P, ... ... Razavi P, et al. Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer. Cell Reports. 43: 114174. PMID 38700982 DOI: 10.1016/j.celrep.2024.114174 |
0.357 |
|
| 2023 |
Kim S, Armand J, Safonov A, Zhang M, Soni RK, Schwartz G, McGuinness JE, Hibshoosh H, Razavi P, Kim M, Chandarlapaty S, Yang HW. Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer. Cell Reports. 42: 113198. PMID 37865915 DOI: 10.1016/j.celrep.2023.113198 |
0.309 |
|
| 2023 |
Nagaraj G, Vinayak S, Khaki AR, Sun T, Kuderer NM, Aboulafia DM, Acoba JD, Awosika J, Bakouny Z, Balmaceda NB, Bao T, Bashir B, Berg S, Bilen MA, Bindal P, ... ... Razavi P, et al. Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: a COVID-19 and cancer consortium (CCC19) cohort study. Elife. 12. PMID 37846664 DOI: 10.7554/eLife.82618 |
0.317 |
|
| 2023 |
Nagaraj G, Vinayak S, Khaki AR, Sun T, Kuderer NM, Aboulafia DM, Acoba JD, Awosika J, Bakouny Z, Balmaceda NB, Bao T, Bashir B, Berg S, Bilen MA, Bindal P, ... ... Razavi P, et al. Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Medrxiv : the Preprint Server For Health Sciences. PMID 37205429 DOI: 10.1101/2023.03.09.23287038 |
0.376 |
|
| 2022 |
Vahdatinia M, Derakhshan F, Da Cruz Paula A, Dopeso H, Marra A, Gazzo AM, Brown D, Selenica P, Ross DS, Razavi P, Zhang H, Weigelt B, Wen HY, Brogi E, Reis-Filho JS, et al. genetic alterations in breast cancer. Journal of Clinical Pathology. PMID 36323507 DOI: 10.1136/jcp-2022-208611 |
0.367 |
|
| 2022 |
Grabenstetter A, Brogi E, Zhang H, Razavi P, Reis-Filho JS, VanZee KJ, Norton L, Wen HY. Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy. Npj Breast Cancer. 8: 93. PMID 35953528 DOI: 10.1038/s41523-022-00469-z |
0.312 |
|
| 2022 |
Lloyd MR, Wander SA, Hamilton E, Razavi P, Bardia A. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. Therapeutic Advances in Medical Oncology. 14: 17588359221113694. PMID 35923930 DOI: 10.1177/17588359221113694 |
0.353 |
|
| 2022 |
Satyanarayana G, Enriquez KT, Sun T, Klein EJ, Abidi M, Advani SM, Awosika J, Bakouny Z, Bashir B, Berg S, Bernardes M, Egan PC, Elkrief A, Feldman LE, Friese CR, ... ... Razavi P, et al. Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study. Open Forum Infectious Diseases. 9: ofac037. PMID 35198648 DOI: 10.1093/ofid/ofac037 |
0.323 |
|
| 2022 |
Nguyen B, Fong C, Luthra A, Smith SA, DiNatale RG, Nandakumar S, Walch H, Chatila WK, Madupuri R, Kundra R, Bielski CM, Mastrogiacomo B, Donoghue MTA, Boire A, Chandarlapaty S, ... ... Razavi P, et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell. 185: 563-575.e11. PMID 35120664 DOI: 10.1016/j.cell.2022.01.003 |
0.366 |
|
| 2021 |
Smith AE, Ferraro E, Safonov A, Morales CB, Lahuerta EJA, Li Q, Kulick A, Ross D, Solit DB, de Stanchina E, Reis-Filho J, Rosen N, Arribas J, Razavi P, Chandarlapaty S. HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nature Communications. 12: 6667. PMID 34795269 DOI: 10.1038/s41467-021-27093-y |
0.361 |
|
| 2021 |
Schwartz CJ, da Silva EM, Marra A, Gazzo AM, Selenica P, Rai VK, Mandelker D, Pareja F, Misyura M, D'Alfonso TM, Brogi E, Drullinsky P, Razavi P, Robson ME, Drago JZ, et al. Morphological and genomic characteristics of breast cancers occurring in individuals with Lynch Syndrome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34667028 DOI: 10.1158/1078-0432.CCR-21-2027 |
0.361 |
|
| 2021 |
Rose Brannon A, Jayakumaran G, Diosdado M, Patel J, Razumova A, Hu Y, Meng F, Haque M, Sadowska J, Murphy BJ, Baldi T, Johnson I, Ptashkin R, Hasan M, Srinivasan P, ... ... Razavi P, et al. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature Communications. 12: 3770. PMID 34145282 DOI: 10.1038/s41467-021-24109-5 |
0.304 |
|
| 2021 |
da Silva EM, Selenica P, Vahdatinia M, Pareja F, Da Cruz Paula A, Ferrando L, Gazzo AM, Dopeso H, Ross DS, Bakhteri A, Riaz N, Chandarlapaty S, Razavi P, Norton L, Wen HY, et al. TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. Npj Breast Cancer. 7: 43. PMID 33863915 DOI: 10.1038/s41523-021-00250-8 |
0.349 |
|
| 2021 |
Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, ... ... Razavi P, et al. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. Npj Breast Cancer. 7: 44. PMID 33863913 DOI: 10.1038/s41523-021-00251-7 |
0.402 |
|
| 2021 |
Cai Y, Xu G, Wu F, Michelini F, Chan C, Qu X, Selenica P, Ladewig E, Castel P, Cheng Y, Zhao A, Jhaveri K, Toska E, Jimenez M, Jacquet Jacquet A, ... ... Razavi P, et al. Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit sensitivity to PI3Kα inhibitors. Cancer Research. PMID 33685991 DOI: 10.1158/0008-5472.CAN-20-3232 |
0.365 |
|
| 2020 |
Billena C, Wilgucki M, Flynn J, Modlin L, Tadros A, Razavi P, Braunstein LZ, Gillespie E, Cahlon O, McCormick B, Zhang Z, Morrow M, Powell S, Khan AJ. 10-Year Breast Cancer Outcomes in Women ≤35 Years of Age. International Journal of Radiation Oncology, Biology, Physics. PMID 33371964 DOI: 10.1016/j.ijrobp.2020.10.022 |
0.309 |
|
| 2020 |
Billena C, Wilgucki M, Flynn J, Modlin L, Tadros A, Razavi P, Braunstein LZ, Gillespie E, Cahlon O, McCormick B, Zhang Z, Morrow M, Powell S, Khan AJ. 10-Year Breast Cancer Outcomes in Women ≤35 Years of Age. International Journal of Radiation Oncology, Biology, Physics. PMID 33371964 DOI: 10.1016/j.ijrobp.2020.10.022 |
0.309 |
|
| 2020 |
Gao SP, Kiliti AJ, Zhang K, Vasani N, Mao N, Jordan E, Wise HC, Shrestha Bhattarai T, Hu W, Dorso M, Rodrigues JA, Kim K, Hanrahan AJ, Razavi P, Carver B, et al. AKT1 E17K inhibits cancer cell migration by abrogating β-catenin signaling. Molecular Cancer Research : McR. PMID 33303690 DOI: 10.1158/1541-7786.MCR-20-0623 |
0.325 |
|
| 2020 |
Ros S, Wright AJ, D'Santos P, Hu DE, Hesketh RL, Lubling Y, Georgopoulou D, Lerda G, Couturier DL, Razavi P, Pelossof R, Batra AS, Mannion E, Lewis DY, Martin A, et al. Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER Breast Cancer. Cancer Cell. PMID 32976773 DOI: 10.1016/j.ccell.2020.08.016 |
0.353 |
|
| 2020 |
Mateo L, Duran-Frigola M, Gris-Oliver A, Palafox M, Scaltriti M, Razavi P, Chandarlapaty S, Arribas J, Bellet M, Serra V, Aloy P. Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. Genome Medicine. 12: 78. PMID 32907621 DOI: 10.1186/S13073-020-00774-X |
0.323 |
|
| 2020 |
Arruabarrena-Aristorena A, Maag JLV, Kittane S, Cai Y, Karthaus WR, Ladewig E, Park J, Kannan S, Ferrando L, Cocco E, Ho SY, Tan DS, Sallaku M, Wu F, Acevedo B, ... ... Razavi P, et al. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. Cancer Cell. PMID 32888433 DOI: 10.1016/J.Ccell.2020.08.003 |
0.491 |
|
| 2020 |
Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, Vasan N, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, et al. Alterations in and promote clinical resistance to alpelisib plus aromatase inhibitors. Nature Cancer. 1: 382-393. PMID 32864625 DOI: 10.1038/S43018-020-0047-1 |
0.429 |
|
| 2020 |
Hoda RS, Bowman AS, Zehir A, Razavi P, Brogi E, Ladanyi M, Arcila ME, Wen HY, Ross DS. Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status in Invasive Breast Carcinoma: A Focus on Group 4 Using the 2018 ASCO/CAP HER2 Testing Guideline. Histopathology. PMID 32841416 DOI: 10.1111/His.14241 |
0.361 |
|
| 2020 |
Wang DG, Barrios DM, Blinder VS, Bromberg JF, Drullinsky PR, Funt SA, Jhaveri KL, Lake DE, Lyons T, Modi S, Razavi P, Sidel M, Traina TA, Vahdat LT, Lacouture ME. Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer. Breast Cancer Research and Treatment. PMID 32613539 DOI: 10.1007/S10549-020-05726-Y |
0.438 |
|
| 2020 |
Sutton EJ, Onishi N, Fehr DA, Dashevsky BZ, Sadinski M, Pinker K, Martinez DF, Brogi E, Braunstein L, Razavi P, El-Tamer M, Sacchini V, Deasy JO, Morris EA, Veeraraghavan H. A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy. Breast Cancer Research : Bcr. 22: 57. PMID 32466777 DOI: 10.1186/S13058-020-01291-W |
0.432 |
|
| 2020 |
Ross DS, Liu B, Schram AM, Razavi P, Lagana SM, Zhang Y, Scaltriti M, Bromberg JF, Ladanyi M, Hyman DM, Drilon A, Zehir A, Benayed R, Chandarlapaty S, Hechtman JF. Enrichment of Kinase Fusions in ESR1 Wild Type, Metastatic Breast Cancer Revealed by a Systematic Analysis of 4,854 Patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32348852 DOI: 10.1016/J.Annonc.2020.04.008 |
0.463 |
|
| 2020 |
Gris-Oliver A, Palafox M, Monserrat L, Brasó-Maristany F, Òdena A, Sánchez-Guixé M, Ibrahim YH, Villacampa G, Grueso J, Parés M, Guzman M, Rodriguez O, Bruna A, Hirst CS, Barnicle A, ... ... Razavi P, et al. Genetic alterations in the PI3K/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer patient-derived xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32220884 DOI: 10.1158/1078-0432.Ccr-19-3324 |
0.477 |
|
| 2020 |
Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, ... ... Razavi P, et al. HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discovery. PMID 32213539 DOI: 10.1158/2159-8290.Cd-20-0215 |
0.424 |
|
| 2020 |
Xu G, Chhangawala S, Cocco E, Razavi P, Cai Y, Otto JE, Ferrando L, Selenica P, Ladewig E, Chan C, Da Cruz Paula A, Witkin M, Cheng Y, Park J, Serna-Tamayo C, et al. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nature Genetics. PMID 31932695 DOI: 10.1038/S41588-019-0554-0 |
0.448 |
|
| 2020 |
Murciano-Goroff YR, Hui AB, Chabon JJ, Moding EJ, Lebow ES, Araujo-Filho JA, Isbell JM, Jones DR, Ginsberg MS, Myers ML, Offin M, Drilon AE, Hellmann MD, Lai WV, Reis-Filho JS, ... Razavi P, et al. Early ctDNA response assessment for prediction of platinum sensitivity in small cell lung cancer. Journal of Clinical Oncology. 38: 9067-9067. DOI: 10.1200/Jco.2020.38.15_Suppl.9067 |
0.408 |
|
| 2020 |
Lebow ES, Murciano-Goroff YR, Brannon AR, Zehir A, Arcila ME, Benayed R, Chaft JE, Drilon AE, Kris MG, Gomez DR, Razavi P, Reis-Filho JS, Jones DR, Rudin CM, Isbell JM, et al. MSK-ACCESS for noninvasive somatic mutation profiling of lung cancers utilizing circulating tumor DNA. Journal of Clinical Oncology. 38: 3529-3529. DOI: 10.1200/Jco.2020.38.15_Suppl.3529 |
0.42 |
|
| 2020 |
Comen EA, Razavi P, Patel PB, Martin A, Seshan VE, Mandelker D, Ptashkin R, Kemel Y, Stadler ZK, Ladanyi M, Berger MF, Zehir A, Robson ME, Reis-Filho JS, Norton L, et al. Evaluating the association between clonal hematopoiesis and germline pathogenic and likely pathogenic variants in cancer predisposition genes. Journal of Clinical Oncology. 38: 1535-1535. DOI: 10.1200/Jco.2020.38.15_Suppl.1535 |
0.377 |
|
| 2020 |
S DMBM, Wang DG, Blinder VS, Bromberg J, Drullinsky P, Funt SA, Jhaveri KL, Lake D, Lyons T, Modi S, Razavi P, Sidel M, Traina TA, Vahdat LT, Lacouture ME. Prevalence and characterization of dermatologic adverse events related to alpelisib (BYL719) in breast cancer patients. Journal of Clinical Oncology. 38: 1063-1063. DOI: 10.1200/Jco.2020.38.15_Suppl.1063 |
0.454 |
|
| 2020 |
Murciano-Goroff YR, Lebow ES, Tu H, Li M, Lim LP, Arbour KC, Travis W, Solit DB, Ladanyi M, Jones DR, Rudin CM, Martinez A, Myers ML, Makhnin A, Razavi P, et al. Abstract 12: Characterizing KRAS G12C and other mutations in plasma ctDNA from patients with lung cancer Clinical Cancer Research. 26: 12-12. DOI: 10.1158/1557-3265.Advprecmed20-12 |
0.428 |
|
| 2020 |
Pareja F, Lee SS, Beca F, Ferrando L, Selenica P, Brown DN, Wen HY, Zhang H, Brogi E, Razavi P, Chandarlapaty S, Weigelt B, Reis-Filho JS. Abstract PD8-06: The genomic landscape of metastatic special histologic types of breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Pd8-06 |
0.46 |
|
| 2020 |
Drago JZ, Serna-Tamayo C, Anjos CHD, Brown DN, Modi S, Jhaveri K, Solit DB, Traina TA, Chandarlapaty S, Reis-Filho JS, Robson ME, Gucalp A, Razavi P. Abstract P4-17-01: Genomic profiling of primary and metastatic breast cancer in men Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P4-17-01 |
0.516 |
|
| 2020 |
Selenica P, Pareja F, Tadros A, Ferrando L, Brown DN, Zhang H, Razavi P, Mandelker D, Robson ME, Chandarlapaty S, Weigelt B, Reis-Filho JS. Abstract P4-05-08: Genomic landscape of breast cancer occurring in elderly individuals Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P4-05-08 |
0.48 |
|
| 2020 |
Selenica P, Pareja F, Ferrando L, Brown DN, Riaz N, Weigelt B, Drago JZ, Robson ME, Razavi P, Chandarlapaty S, Reis-Filho JS. Abstract P4-05-01: Massively parallel sequencing analysis of microsatellite instability in breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P4-05-01 |
0.441 |
|
| 2020 |
Vasan N, Razavi P, Johnson JL, Shao H, Wilson T, Schimmoller F, Shah H, Antoine A, Ladewig E, Gorelick A, Lin T, Toska E, Xu G, Kazmi A, Chang MT, et al. Abstract P3-03-01: Double PIK3CA mutations in cis drive oncogene addiction and enhance sensitivity to PI3K alpha inhibitors in breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-03-01 |
0.508 |
|
| 2020 |
Serna-Tamayo C, Drago JZ, Anjos CD, Herbert J, Pareja F, Modi S, Jhaveri K, Dang C, Solit DB, Norton L, Scaltriti M, Reis-Filho JS, Chandarlapaty S, Robson ME, Razavi P. Abstract P2-10-01: The genomic landscape of breast cancer in African American women Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-10-01 |
0.492 |
|
| 2020 |
Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Schram A, Varga A, Wong A, Ambrose H, Barnicle A, Carr TH, Bruin ECd, Salinas-Souza C, Foxley A, ... ... Razavi P, et al. Abstract P1-19-05: Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-19-05 |
0.479 |
|
| 2020 |
Razavi P. Abstract ES4-3: The genomic landscape of endocrine-resistant metastatic breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Es4-3 |
0.487 |
|
| 2020 |
Murciano-Goroff YR, Arbour KC, Offin MD, Tu HY, Lebow ES, Shaffer TS, Bertucci C, Hosseini SA, Garg K, Lim LP, Li M, Chang JC, Reis-Filho JS, Razavi P, Isbell JM, et al. Abstract 709: The utility of plasma ctDNA for detection ofKRASG12C and other mutations in lung cancers Clinical Trials. DOI: 10.1158/1538-7445.Am2020-709 |
0.365 |
|
| 2019 |
Mondaca S, Razavi P, Xu C, Offin M, Myers M, Scaltriti M, Hechtman JF, Bradley M, O'Reilly EM, Berger MF, Solit DB, Li BT, Abou-Alfa GK. Genomic Characterization of -Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine. Jco Precision Oncology. 3. PMID 32923849 DOI: 10.1200/PO.19.00223 |
0.353 |
|
| 2019 |
Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, Abida W, Juluru K, De Bruijn I, Hou C, Venn O, Lim R, Anand A, Maddala T, Gnerre S, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature Medicine. PMID 31768066 DOI: 10.1038/S41591-019-0652-7 |
0.417 |
|
| 2019 |
Penson A, Camacho N, Zheng Y, Varghese AM, Al-Ahmadie H, Razavi P, Chandarlapaty S, Vallejo CE, Vakiani E, Gilewski T, Rosenberg JE, Shady M, Tsui DWY, Reales DN, Abeshouse A, et al. Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. Jama Oncology. PMID 31725847 DOI: 10.1001/Jamaoncol.2019.3985 |
0.397 |
|
| 2019 |
Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, Ladewig E, Gorelick A, Lin TY, Toska E, Xu G, Kazmi A, Chang MT, Taylor BS, Dickler MN, et al. Double mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. Science (New York, N.Y.). 366: 714-723. PMID 31699932 DOI: 10.1126/Science.Aaw9032 |
0.449 |
|
| 2019 |
Osmanbeyoglu HU, Shimizu F, Rynne-Vidal A, Alonso-Curbelo D, Chen HA, Wen HY, Yeung TL, Jelinic P, Razavi P, Lowe SW, Mok SC, Chiosis G, Levine DA, Leslie CS. Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers. Nature Communications. 10: 4369. PMID 31554806 DOI: 10.1038/S41467-019-12291-6 |
0.452 |
|
| 2019 |
Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, Razavi P, Ptashkin R, Hechtman JF, Toska E, Cownie J, Somwar R, Shifman S, Mattar M, Selçuklu SD, et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine. PMID 31406350 DOI: 10.1038/S41591-019-0542-Z |
0.395 |
|
| 2019 |
Chandarlapaty S, Razavi P. Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900090. PMID 30920879 DOI: 10.1200/Jco.19.00090 |
0.384 |
|
| 2019 |
Li BT, Janku F, Jung B, Hou C, Madwani K, Alden R, Razavi P, Reis-Filho JS, Shen R, Isbell JM, Blocker AW, Eattock N, Gnerre S, Satya RV, Xu H, et al. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30891595 DOI: 10.1093/Annonc/Mdz046 |
0.415 |
|
| 2019 |
Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, ... ... Razavi P, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics. PMID 30643254 DOI: 10.1038/S41588-018-0312-8 |
0.48 |
|
| 2019 |
Li BT, Shen R, Offin M, Buonocore DJ, Myers ML, Venkatesh A, Razavi P, Ginsberg MS, Ulaner GA, Solit DB, Hyman DM, Rudin CM, Gedvilaite E, Tsui D, Arcila ME, et al. Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial. Journal of Clinical Oncology. 37: 6001-6001. DOI: 10.1200/Jco.2019.37.15_Suppl.6001 |
0.392 |
|
| 2019 |
Drago JZ, Latham A, Modi S, Razavi P, Stadler ZK, Robson ME. Detection of subthreshold microsatellite instability in breast cancer: An ongoing investigation. Journal of Clinical Oncology. 37: 1089-1089. DOI: 10.1200/Jco.2019.37.15_Suppl.1089 |
0.501 |
|
| 2019 |
dos Anjos CH, Razavi P, Herbert J, Colon J, Gill K, Modi S, Bromberg J, Dang CT, Liu D, Norton L, Chandarlapaty S, Robson ME, Jhaveri KL. A large retrospective analysis of CDK 4/6 inhibitor retreatment in ER+ metastatic breast cancer (MBC). Journal of Clinical Oncology. 37: 1053-1053. DOI: 10.1200/Jco.2019.37.15_Suppl.1053 |
0.316 |
|
| 2019 |
Razavi P, Anjos CHd, Brown DN, Qing L, Ping C, Herbert J, Colon J, Liu D, Mao M, Norton L, Scaltriti M, Solit DB, Robson ME, Reis-Filho JS, Jhaveri KL, et al. Molecular profiling of ER+ metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors. Journal of Clinical Oncology. 37: 1009-1009. DOI: 10.1200/Jco.2019.37.15_Suppl.1009 |
0.451 |
|
| 2019 |
Toy W, Carlson K, Martin T, Razavi P, Berger M, Baselga J, Greene G, Katzenellenbogen J, Chandarlapaty S. Abstract P5-04-11: Non-canonical, clinical ESR1 mutations promote resistance to antiestrogen therapies Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P5-04-11 |
0.326 |
|
| 2019 |
Toska E, Xu G, Chhangawala S, Cocco E, Razavi P, Otto J, Cai Y, Chan C, Avino DRD, Collings C, Levine RL, Scaltriti M, Reis-Filho JS, Kadoch C, Leslie C, et al. Abstract 949: ARID1A is a critical regulator of luminal identity and therapeutic response in estrogen receptor-positive breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-949 |
0.423 |
|
| 2019 |
Cocco E, Kulick A, Misale S, Yaeger R, Razavi P, Won HH, Ptashkin R, Hechtman JF, Toska E, Cownie J, Somwar R, Shifman S, Mattar M, Selçuklu SD, Samoila A, et al. Abstract LB-118: Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-118 |
0.44 |
|
| 2019 |
Razavi P, Li Q, Li Z, Brown DN, Ping C, Shen R, Sanchez-Vega F, Schultz ND, Baselga J, Scaltriti M, Reis-Filho JS, Chandarlapaty S. Abstract 927: Genomic profiling of metastatic breast cancer identifies the Hippo pathway to be a key determinant of CDK4/6 inhibitor sensitivity Cancer Research. 79: 927-927. DOI: 10.1158/1538-7445.Am2019-927 |
0.498 |
|
| 2019 |
Li Q, Razavi P, Li Z, Paula AFDC, Brogi E, Scaltriti M, Reis-Filho JS, Chandarlapaty S. Abstract 4413: CDK6 overexpression promotes resistance to CDK4/6 inhibitors in breast cancer Cancer Research. 79: 4413-4413. DOI: 10.1158/1538-7445.Am2019-4413 |
0.402 |
|
| 2019 |
Vasan N, Razavi P, Johnson J, Shao H, Shah H, Antoine A, Ladewig E, Gorelick A, Toska E, Xu G, Kazmi A, Chang MT, Taylor BS, Dickler MN, Jhaveri K, et al. Abstract 3917: DoublePIK3CAmutations incisenhance oncogene activation and sensitivity to PI3K alpha inhibitors in breast cancer Cancer Research. 79: 3917-3917. DOI: 10.1158/1538-7445.Am2019-3917 |
0.496 |
|
| 2019 |
Vasan N, Razavi P, Johnson J, Shao H, Reznik E, Smith M, Sebra R, Cantley L, Scaltriti M, Baselga J. Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer Annals of Oncology. 30: iii1. DOI: 10.1093/Annonc/Mdz095 |
0.479 |
|
| 2019 |
Tu H, Xu C, Tong-Li C, Offin M, Razavi P, Schapira E, Namakydoust A, Lee A, Pavlakis N, Clarke S, Diakos C, Chan D, Myers M, Makhnin A, Jain H, et al. P1.01-122 A Clinical Utility Study of Plasma DNA Next Generation Sequencing Guided Treatment of Uncommon Drivers in Advanced Non-Small-Cell Lung Cancers Journal of Thoracic Oncology. 14: S410. DOI: 10.1016/J.Jtho.2019.08.837 |
0.347 |
|
| 2019 |
Modlin L, Billena C, Wilgucki M, Braunstein L, Cahlon O, McCormick B, Tadros A, Razavi P, Morrow M, Cody H, Robson M, Powell S, Khan A, Gillespie E. Genetic Testing in Ultra-Young Breast Cancer Patients: A Single Institution Analysis of Breast Cancer Patients ≤ 35 Years at Diagnosis International Journal of Radiation Oncology*Biology*Physics. 105: E43-E44. DOI: 10.1016/J.Ijrobp.2019.06.715 |
0.467 |
|
| 2019 |
Khan A, Billena C, Wilgucki M, Flynn J, Modlin L, Tadros A, Razavi P, Braunstein L, Gillespie E, Cahlon O, McCormick B, Zhang Z, Morrow M, Powell S. Breast Cancer in Patients Age ≤ 35 Years: Overall Survival, Disease-Free Survival, Secondary Malignancies, and Contralateral Breast Cancers Rates across 10 Years of Follow-Up International Journal of Radiation Oncology*Biology*Physics. 105: E25-E26. DOI: 10.1016/J.Ijrobp.2019.06.673 |
0.439 |
|
| 2019 |
Billena C, Brown D, Selenica P, Braunstein LZ, Reis-Filho J, Powell SN, Razavi P, Khan AJ. Phylogenetic Relationship Between Locoregional Recurrences and Distant Metastasis in Breast Cancer International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.1035 |
0.441 |
|
| 2018 |
Gupta S, Vanderbilt CM, Cotzia P, Arias Stella JA, Chang JC, Zehir A, Benayed R, Nafa K, Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME, Ross DS. Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management. The Journal of Molecular Diagnostics : Jmd. PMID 30576871 DOI: 10.1016/J.Jmoldx.2018.10.006 |
0.472 |
|
| 2018 |
Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, et al. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell. 34: 893-905.e8. PMID 30537512 DOI: 10.1016/J.Ccell.2018.11.006 |
0.445 |
|
| 2018 |
Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, et al. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling. 11. PMID 30301790 DOI: 10.1126/Scisignal.Aat9773 |
0.48 |
|
| 2018 |
Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 34: 427-438.e6. PMID 30205045 DOI: 10.1016/J.Ccell.2018.08.008 |
0.47 |
|
| 2018 |
Ross DS, Zehir A, Brogi E, Konno F, Krystel-Whittemore M, Edelweiss M, Berger MF, Toy W, Chandarlapaty S, Razavi P, Baselga J, Wen HY. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 30158597 DOI: 10.1038/S41379-018-0116-5 |
0.525 |
|
| 2018 |
Bielski CM, Zehir A, Penson AV, Donoghue MTA, Chatila W, Armenia J, Chang MT, Schram AM, Jonsson P, Bandlamudi C, Razavi P, Iyer G, Robson ME, Stadler ZK, Schultz N, et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nature Genetics. PMID 30013179 DOI: 10.1038/S41588-018-0165-1 |
0.498 |
|
| 2018 |
Gala K, Li Q, Sinha A, Razavi P, Dorso M, Sanchez-Vega F, Chung YR, Hendrickson R, Hsieh J, Berger M, Schultz N, Pastore A, Abdel-Wahab O, Chandarlapaty S. KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function. Oncogene. PMID 29755131 DOI: 10.1038/S41388-018-0273-5 |
0.468 |
|
| 2018 |
Xu C, Myers M, Buonocore DJ, Razavi P, Shen R, Lai WV, Smyth LM, Zheng T, Ni A, Solit DB, Zehir A, Brzostowski EB, Hellmann MD, Drilon AE, Rudin CM, et al. Refining actionable HER2 alterations in lung cancers through next generation sequencing (NGS). Journal of Clinical Oncology. 36: e24181-e24181. DOI: 10.1200/Jco.2018.36.15_Suppl.E24181 |
0.381 |
|
| 2018 |
Xu C, Zhang Y, Liu D, Shen R, Razavi P, Liu S, Sun H, Offin M, Drilon A, Rudin C, Arcila M, Wu Y, Li B. P1.01-99 Detecting HER2 Alterations by Next Generation Sequencing (NGS) in Patients with Advanced NSCLC from the United States and China Journal of Thoracic Oncology. 13: S502. DOI: 10.1016/J.Jtho.2018.08.655 |
0.305 |
|
| 2017 |
Chang MT, Shrestha Bhattarai T, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, Chakravarty D, Phillips S, Kandoth C, Penson A, Gorelick A, Shamu T, Patel S, Harris C, Gao J, ... ... Razavi P, et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discovery. PMID 29247016 DOI: 10.1158/2159-8290.Cd-17-0321 |
0.487 |
|
| 2017 |
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, ... ... Razavi P, et al. Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine. 23: 1004. PMID 28777785 DOI: 10.1038/nm0817-1004c |
0.35 |
|
| 2017 |
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, ... ... Razavi P, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine. PMID 28481359 DOI: 10.1038/Nm.4333 |
0.43 |
|
| 2017 |
Offin M, Chabon JJ, Razavi P, Isbell JM, Rudin CM, Diehn M, Li BT. Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. Journal of Oncology. 2017: 4517834. PMID 28392802 DOI: 10.1155/2017/4517834 |
0.418 |
|
| 2017 |
Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, et al. A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Investigational New Drugs. PMID 28281183 DOI: 10.1007/S10637-017-0445-0 |
0.302 |
|
| 2017 |
Razavi P, Li BT, Abida W, Aravanis A, Jung B, Shen R, Hou C, De Bruijn I, Gnerre S, Lim RS, Reales D, Maddala T, Berger MF, Riely GJ, Scher HI, et al. Performance of a high-intensity 508-gene circulating-tumor DNA (ctDNA) assay in patients with metastatic breast, lung, and prostate cancer. Journal of Clinical Oncology. 35: LBA11516-LBA11516. DOI: 10.1200/Jco.2017.35.15_Suppl.Lba11516 |
0.411 |
|
| 2017 |
Razavi P, Li BT, Hou C, Shen R, Venn O, Lim RS, Hubbell E, De Bruijn I, Liu Q, Vijaya Satya R, Xu H, Shen L, Sehnert A, Maddala T, Berger MF, et al. Cell-free DNA (cfDNA) mutations from clonal hematopoiesis: Implications for interpretation of liquid biopsy tests. Journal of Clinical Oncology. 35: 11526-11526. DOI: 10.1200/Jco.2017.35.15_Suppl.11526 |
0.467 |
|
| 2017 |
Toy W, Carlson KE, Martin TA, Mayne CG, Fanning SW, Razavi P, Baselga J, Shen Y, Greene G, Katzenellenbogen B, Katzenellenbogen J, Chandarlapaty S. Abstract 999: ESR1 mutations activate and confer hormone resistance via distinct mechanisms Endocrinology. 77: 999-999. DOI: 10.1158/1538-7445.Am2017-999 |
0.307 |
|
| 2017 |
Penson A, Camacho N, Varghese AM, Abeshouse A, Razavi P, Syed A, Zehir A, Schultz N, Solit DB, Hyman D, Taylor BS, Berger MF. Abstract 971: Genome directed diagnosis informs clinical cancer care Cancer Research. 77: 971-971. DOI: 10.1158/1538-7445.Am2017-971 |
0.335 |
|
| 2016 |
Ross DS, Zehir A, Cheng DT, Benayed R, Nafa K, Hechtman JF, Janjigian YY, Weigelt B, Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME. Next-Generation Assessment of ERBB2 (Human Epidermal Growth Factor Receptor 2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. The Journal of Molecular Diagnostics : Jmd. PMID 28027945 DOI: 10.1016/J.Jmoldx.2016.09.010 |
0.436 |
|
| 2016 |
Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, Smith A, Wilson J, Morrow C, Wong WL, De Stanchina E, Carlson KE, Martin TS, Uddin S, Li Z, et al. Activating ESR1 Mutations Differentially Impact the Efficacy of ER Antagonists. Cancer Discovery. PMID 27986707 DOI: 10.1158/2159-8290.CD-15-1523 |
0.304 |
|
| 2016 |
Le X, Antony R, Razavi P, Treacy DJ, Luo F, Ghandi M, Castel P, Scaltriti M, Baselga J, Garraway LA. Systematic functional characterization of resistance to PI3K inhibition in breast cancer. Cancer Discovery. PMID 27604488 DOI: 10.1158/2159-8290.Cd-16-0305 |
0.464 |
|
| 2016 |
Castel P, Ellis H, Bago R, Toska E, Razavi P, Carmona FJ, Kannan S, Verma CS, Dickler M, Chandarlapaty S, Brogi E, Alessi DR, Baselga J, Scaltriti M. PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition. Cancer Cell. PMID 27451907 DOI: 10.1016/J.Ccell.2016.06.004 |
0.398 |
|
| 2016 |
Smyth LM, Reichel JB, Tang J, Patel JAA, Meng F, Selcuklu SD, You D, Samoila A, Schiavon G, Li BT, Razavi P, Piscuoglio S, Reis-Filho JS, Hudis CA, Baselga J, et al. Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363). Journal of Clinical Oncology. 34: 11500-11500. DOI: 10.1200/Jco.2016.34.15_Suppl.11500 |
0.372 |
|
| 2016 |
Gucalp A, Proverbs-Singh T, Razavi P, Chandarlapaty S, Patil S, Ross D, Zehir A, Baselga J, Hudis C, Traina T. Abstract P6-07-08: Androgen receptor (AR) mutations in a cohort of patients with breast cancer (BC) who have undergone tumor genomic profiling Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-07-08 |
0.532 |
|
| 2016 |
Toy W, Weir H, Razavi P, Berger M, Wong WL, Stanchina ED, Baselga J, Chandarlapaty S. Abstract 863: Differential activity and SERD sensitivity of clinical ESR1 mutations Cancer Research. 76: 863-863. DOI: 10.1158/1538-7445.Am2016-863 |
0.429 |
|
| 2016 |
Razavi P, Chang MT, Middha S, Ross DS, Zehir A, Proverbs-Singh TA, Kandoth C, Chandarlapaty S, Dickler MN, Reis-Filho JS, Patil S, Seshan V, Smyth L, Iyengar NM, Jhaveri K, et al. Abstract 4509: Clinical genomic profiling of 1000 metastatic breast cancer patients: actionable targets, novel alterations, and clinical correlations Cancer Research. 76: 4509-4509. DOI: 10.1158/1538-7445.Am2016-4509 |
0.539 |
|
| 2016 |
Castel P, Ellis H, Bago R, Toska E, Srinivasaraghavan K, Carmona FJ, Razavi P, Verma C, Dickler M, Chandarlapaty S, Brogi E, Alessi D, Baselga J, Scaltriti M. Abstract 2107: PDK1 blockade overcomes intrinsic resistance to PI3Kα inhibition Cancer Research. 76: 2107-2107. DOI: 10.1158/1538-7445.Am2016-2107 |
0.416 |
|
| 2015 |
Ross DS, Zehir A, Cheng DT, Nafa K, Jour G, Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME. The clinical utility of ERBB2 amplification detection in breast carcinoma using a 341 gene hybrid capture-based next generation sequencing (NGS) assay: Comparison with standard immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) assays. Journal of Clinical Oncology. 33: 604-604. DOI: 10.1200/Jco.2015.33.15_Suppl.604 |
0.366 |
|
| 2014 |
Ailawadhi S, Swaika A, Razavi P, Yang D, Chanan-Khan A. Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups Blood Cancer Journal. 4. PMID 25192415 DOI: 10.1038/Bcj.2014.63 |
0.312 |
|
| 2013 |
Razavi P, Rand KA, Cozen W, Chanan-Khan A, Usmani S, Ailawadhi S. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer Journal. 3: e121. PMID 23811785 DOI: 10.1038/Bcj.2013.19 |
0.369 |
|
| 2013 |
Schernhammer ES, Sperati F, Razavi P, Agnoli C, Sieri S, Berrino F, Krogh V, Abbagnato C, Grioni S, Blandino G, Schunemann HJ, Muti P. Endogenous sex steroids in premenopausal women and risk of breast cancer: the ORDET cohort. Breast Cancer Research : Bcr. 15: R46. PMID 23777922 DOI: 10.1186/Bcr3438 |
0.418 |
|
| 2012 |
Wu AH, Vigen C, Razavi P, Tseng CC, Stancyzk FZ. Alcohol and breast cancer risk among Asian-American women in Los Angeles County. Breast Cancer Research : Bcr. 14: R151. PMID 23185976 DOI: 10.1186/Bcr3363 |
0.37 |
|
| 2012 |
Razavi P, Lee E, Bernstein L, Van Den Berg D, Horn-Ross PL, Ursin G. Variations in sex hormone metabolism genes, postmenopausal hormone therapy and risk of endometrial cancer. International Journal of Cancer. Journal International Du Cancer. 130: 1629-38. PMID 21544810 DOI: 10.1002/Ijc.26163 |
0.524 |
|
| 2012 |
Ali S, Dilday E, Tagawa S, Akhtar NH, Liebman HA, Razavi P, Rochanda L, Quinn DI, Seaton K, O'Connell CL. D-Dimer Levels Among Cancer Patients with Unsuspected Pulmonary Embolism: Clinical Correlates and Relevance Blood. 120: 1154-1154. DOI: 10.1182/Blood.V120.21.1154.1154 |
0.369 |
|
| 2011 |
Schernhammer ES, Razavi P, Li TY, Qureshi AA, Han J. Rotating night shifts and risk of skin cancer in the nurses' health study. Journal of the National Cancer Institute. 103: 602-6. PMID 21335547 DOI: 10.1093/Jnci/Djr044 |
0.354 |
|
| 2011 |
O'Connell C, Razavi P, Ghalichi M, Boyle S, Vasan S, Mark L, Caton A, Duddalwar V, Boswell W, Grabow K, Liebman HA. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. Journal of Thrombosis and Haemostasis : Jth. 9: 305-11. PMID 20955348 DOI: 10.1111/J.1538-7836.2010.04114.X |
0.383 |
|
| 2011 |
Razavi P, Rand KA, Ailawadhi S. Trends in Incidence and Survival of Multiple Myeloma with Second Primary Malignancy, Blood. 118: 3958-3958. DOI: 10.1182/Blood.V118.21.3958.3958 |
0.308 |
|
| 2010 |
Lee E, Hsu C, Haiman CA, Razavi P, Horn-Ross PL, Van Den Berg D, Bernstein L, Le Marchand L, Henderson BE, Setiawan VW, Ursin G. Genetic variation in the progesterone receptor gene and risk of endometrial cancer: a haplotype-based approach. Carcinogenesis. 31: 1392-9. PMID 20547493 DOI: 10.1093/Carcin/Bgq113 |
0.539 |
|
| 2010 |
Razavi P, Pike MC, Horn-Ross PL, Templeman C, Bernstein L, Ursin G. Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 19: 475-83. PMID 20086105 DOI: 10.1158/1055-9965.Epi-09-0712 |
0.545 |
|
| 2010 |
Ailawadhi S, Yang D, Ho E, Razavi P, Chanan-Khan AA. Outcome Disparities In Multiple Myeloma: A SEER-Based Comparative Analysis of Hispanic Patients Blood. 116: 396-396. DOI: 10.1182/Blood.V116.21.396.396 |
0.32 |
|
| 2010 |
Gowin K, Piatek CI, Saadat S, Cuadra K, Razavi P, Tang R, O'Connell CL. Patients with Polycythemia Vera and Essential Thrombocytosis Have a Higher Risk of Prior or Concurrent Tumors Compared to Patients with Secondary Thrombocytosis Blood. 116: 3084-3084. DOI: 10.1182/Blood.V116.21.3084.3084 |
0.389 |
|
| 2009 |
McKean-Cowdin R, Barnholtz-Sloan J, Inskip PD, Ruder AM, Butler M, Rajaraman P, Razavi P, Patoka J, Wiencke JK, Bondy ML, Wrensch M. Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 18: 1118-26. PMID 19318434 DOI: 10.1158/1055-9965.Epi-08-1078 |
0.307 |
|
| 2008 |
O’Connell CL, Ghalichi M, Boyle S, Vasan S, Boswell W, Razavi P, Grabow K, Mark L, Caton A, Liebman H. Unsuspected Pulmonary Emboli Identified on Routine Cancer Staging MDCT Scans: Impact on Cancer Survival Blood. 112: 3818-3818. DOI: 10.1182/Blood.V112.11.3818.3818 |
0.419 |
|
| Show low-probability matches. |